

### AMENDMENTS TO THE CLAIMS

1-2. (canceled)

3. (currently amended) An isolated antibody that selectively binds to a polypeptide of claim 2, wherein the amino acid sequence of said polypeptide consists of SEQ ID NO:2.

4-11. (canceled)

12. (currently amended) A method for detecting the presence of any of the peptides of claim 2 in a sample, said method comprising contacting said sample with a detection agent that specifically allows detection of the presence of the peptide in the sample and then detecting the presence of the peptide, a polypeptide in a sample, wherein the polypeptide has an amino acid sequence consisting of SEQ ID NO:2, and wherein the method comprises:

(a) contacting the sample with an antibody that selectively binds to the polypeptide; and

(b) detecting the binding of the antibody to the polypeptide to thereby detect the polypeptide.

13-23. (canceled)

24. (new) A method for detecting a polypeptide in a sample, wherein the polypeptide has an amino acid sequence comprising SEQ ID NO:2, and wherein the method comprises:

(a) contacting the sample with an antibody that selectively binds to the polypeptide; and

(b) detecting the binding of the antibody to the polypeptide to thereby detect the polypeptide.

25. (new) The method of claim 12, wherein the antibody is coupled to a detectable substance.
26. (new) The method of claim 24, wherein the antibody is coupled to a detectable substance.
27. (new) An isolated antibody that selectively binds to a polypeptide, wherein the amino acid sequence of said polypeptide comprises SEQ ID NO:2.
28. (new) The antibody of claim 3, wherein the antibody is a monoclonal antibody.
29. (new) The antibody of claim 27, wherein the antibody is a monoclonal antibody.
30. (new) The antibody of claim 3, wherein the antibody is coupled to a detectable substance.
31. (new) The antibody of claim 27, wherein the antibody is coupled to a detectable substance.
32. (new) The antibody of claim 28, wherein the antibody is coupled to a detectable substance.
33. (new) The antibody of claim 29, wherein the antibody is coupled to a detectable substance.
34. (new) A composition comprising the antibody of claim 3 and a pharmaceutically acceptable carrier.
35. (new) A composition comprising the antibody of claim 27 and a pharmaceutically acceptable carrier.

36. (new) A composition comprising the antibody of claim 28 and a pharmaceutically acceptable carrier.
37. (new) A composition comprising the antibody of claim 29 and a pharmaceutically acceptable carrier.
38. (new) An isolated antibody fragment that selectively binds to a polypeptide, wherein the amino acid sequence of said polypeptide consists of SEQ ID NO:2, and wherein the antibody fragment comprises a fragment selected from the group consisting of:
- a) an Fab fragment;
  - b) an F(ab')<sub>2</sub> fragment; and
  - c) an Fv fragment.
39. (new) An isolated antibody fragment that selectively binds to a polypeptide, wherein the amino acid sequence of said polypeptide comprises SEQ ID NO:2, and wherein the antibody fragment comprises a fragment selected from the group consisting of:
- a) an Fab fragment;
  - b) an F(ab')<sub>2</sub> fragment; and
  - c) an Fv fragment.